Sana Biotechnology (NASDAQ:SANA – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a ...

A number of analysts have commented on the stock. Jefferies Financial Group began coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They set a “buy” rating and a $7. ...

Pre-earnings options volume in Sana Biotechnology (SANA) is 2.0x normal with calls leading puts 150:1. Implied volatility suggests the market ...

$SANA insiders have traded $SANA stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

SEATTLE - Sana Biotechnology , Inc. (NASDAQ:SANA) reported a narrower-than-expected loss for the fourth quarter of 2024, sending shares up 2.2% in after-hours trading. The biotechnology company ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Sana Biotechnology, Inc. announced encouraging preliminary results from a 12-week clinical study involving hypoimmune-modified pancreatic islet cells for type 1 diabetes, showing persistent C ...

SEATTLE (AP) — SEATTLE (AP) — Sana Biotechnology Inc. (SANA) on Monday reported a loss of $49.1 million in its fourth quarter. The Seattle-based company said it had a loss of 21 cents per share.

(NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the fourth quarter and year ended ...

Sana Biotechnology SANA, a clinical-stage company, is expected to report its fourth-quarter results soon. The company leverages its proprietary hypoimmune technology to develop cell engineering ...